Caplin Point Laboratories Share Price
2796.00-49.00 (-1.72%)
+29.38% past 1 Year
Caplin Point Laboratories is engaged in manufacture of pharmaceuticals formulations. It is a fast-growing Indian pharmaceutical company with global reach, having a 100% export-oriented business. The company supplies a complete
Corporate filings & documents
Announcements
Business Responsibility and Sustainability Report for the Financial Year 2025-26
1 day agoBusiness Responsibility and Sustainability Report for the Financial Year 2025-26
1 day agoNotice of the 35th Annual General Meeting of the Company
1 day agoNotice of the 35th Annual General Meeting of the Company
1 day agoAnnual Report for the Financial Year 2025-26
1 day agoAnnual Report for the Financial Year 2025-26
1 day agoNewspaper Publication for convening 35th AGM of the Company through Video Conferencing.
1 day agoNewspaper Publication for convening 35th AGM of the Company through Video Conferencing.
1 day agoReceipt of Good Manufacturing Practices (GMP) Compliance Certificate by Caplin One Labs Limited (COL) a subsidiary Company from INVIMA
2 days agoReceipt of Good Manufacturing Practices (GMP) Compliance Certificate by Caplin One Labs Limited (COL) a subsidiary Company from INVIMA
2 days agoCompletion of Unannounced USFDA Inspection at the facility of Caplin Steriles Limited (Companys subsidiary)
1 week agoCompletion of Unannounced USFDA Inspection at the facility of Caplin Steriles Limited (Companys subsidiary)
1 week agoTranscript for Earnings call- Q1- FY 2026-27
2 weeks agoTranscript for Earnings call- Q1- FY 2026-27
2 weeks agoAudio Recording of Earnings call for the Quarter ended June 30 2026
3 weeks agoAudio Recording of Earnings call for the Quarter ended June 30 2026
3 weeks agoInvestor Presentation for the Earnings Call for the Quarter ended June 30 2026.
3 weeks agoInvestor Presentation for the Earnings Call for the Quarter ended June 30 2026.
3 weeks agoThe Board of Director in its meeting held today August 12 2026 approved the appointment of directors.
3 weeks agoThe Board of Director in its meeting held today August 12 2026 approved the appointment of directors.
3 weeks agoFinancial Results for the quarter ended June 30 2026
3 weeks agoFinancial Results for the quarter ended June 30 2026
3 weeks agoRecord date for Final Dividend is September 18 2026
3 weeks agoRecord date for Final Dividend is September 18 2026
3 weeks agoBoard meeting outcome for meeting held on August 12 2026
3 weeks agoBoard meeting outcome for meeting held on August 12 2026
3 weeks agoPost-results conference call invite for the quarter ended June 30 2026 is enclosed herewith.
1 month agoPost-results conference call invite for the quarter ended June 30 2026 is enclosed herewith.
1 month agoCaplin Point Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 inter alia to consider and approve 1. Unaudited financial results of the Company for the Quarter ended June 30 2026 (both Standalone & Consolidated)2. recommendation of Final Dividend if any for the FY 2025-26 and fixation of record date for this purpose.
1 month agoCaplin Point Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 inter alia to consider and approve 1. Unaudited financial results of the Company for the Quarter ended June 30 2026 (both Standalone & Consolidated)2. recommendation of Final Dividend if any for the FY 2025-26 and fixation of record date for this purpose.
1 month agoIntimation pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulation 2018 for the quarter ended June 30 2026
1 month agoIntimation pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulation 2018 for the quarter ended June 30 2026
1 month agoIntimation of closure of Trading Window commencing from July 01 2026
2 months agoIntimation of closure of Trading Window commencing from July 01 2026
2 months agoNewspaper advertisement for transfer of Unclaimed dividend and shares to IEPF
2 months agoNewspaper advertisement for transfer of Unclaimed dividend and shares to IEPF
2 months agoAnnual Secretarial Compliance report for the year ended March 31 2026
3 months agoAnnual Secretarial Compliance report for the year ended March 31 2026
3 months agoIntimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
3 months agoIntimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
3 months agoTranscript for Earnings call- Q4- FY 2025-26
3 months agoTranscript for Earnings call- Q4- FY 2025-26
3 months agoEarnings call for Q4(2025-26)
3 months agoPress release regarding receipt of final approval by our subsidiary Caplin Steriles Limited from USFDA for Foscarnet Sodium Injection
3 months agoThe Board at its meeting held today May 14 2026 had declared Interim Dividend of INR.4.00 (200%) per equity share for the FY 2025-26 and fixed the Record date as May 30 2026.
3 months agoFinancial Results for the Quarter and Year ended March 31 2026
3 months agoThe Board at its meeting held today May 14 2026 had 1. Approved the Audited standalone and consolidated financial results of the Company for the year ended March 31 2026 along with Auditors Report.2. Declared an Interim Dividend of INR. 4.00 (200 %) per equity share and fixed the record date as May 30 20263. Approved amendments to Code of Practices and Procedure for Fair Disclosure of Unpublished Price Sensitive Information
3 months agoQ4 post-results conference call invite is enclosed herewith.
3 months agoQ4 post-results conference call invite is enclosed herewith.
3 months agoCaplin Point Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 inter alia to consider and approve Audited financial results of the Company for the year ended March 31 2026 (both Standalone & Consolidated) and declaration of Interim Dividend if any for the FY 2025-26
4 months agoConcalls & investor presentations
Aug 2026
May 2026
Feb 2026
Nov 2025
ConcallPresentation
Aug 2025
ConcallPresentation
May 2025
Feb 2025
Nov 2024
Aug 2024
May 2024
Feb 2024
Nov 2023
Aug 2023
ConcallPresentation
Aug 2023
ConcallPresentation
May 2023
Feb 2023
ConcallPresentation
Nov 2022
Aug 2022
ConcallPresentation
May 2022
ConcallPresentation
Feb 2022
ConcallPresentation
Nov 2021
ConcallPresentation
Oct 2021
ConcallPresentation
May 2021
ConcallPresentation
May 2021
ConcallPresentation
Feb 2021
Nov 2020
ConcallPresentation
Nov 2020
ConcallPresentation
Corporate Actions
Date
Type
Details
2026-09-18
Dividend
4.0
2026-05-29
Dividend
4.0
2025-09-12
Dividend
3.0
2025-05-30
Dividend
3.0
2024-09-23
Dividend
2.5
2024-05-31
Dividend
2.5
2023-09-14
Dividend
2.5
2023-06-09
Dividend
2.0
2022-09-21
Dividend
2.0
2022-05-23
Dividend
2.0
2021-09-20
Dividend
1.5
2021-05-18
Dividend
1.5
2020-09-21
Dividend
0.4
2020-03-12
Dividend
2.1
2019-09-04
Dividend
2.2
2018-09-18
Dividend
2.0
2017-09-07
Dividend
1.5
2016-10-19
Split
10:2
2016-09-01
Dividend
3.5
2016-02-15
Dividend
2.5
2015-10-29
Dividend
5.0
2014-12-11
Dividend
4.0
Company details
Registered office
3rd Floor, “ Ashvich Towers” No.3, Developed Plots Industrial Estate Perungudi Chennai Tamil Nadu PIN: 600096 Tel No: 044-24968000 / 71148000 / 8012772888 Fax No: NULL Email: [email protected] Internet: www.caplinpoint.net
Registrars
II Floor , Kences Towers,No 1 Ramakrishna Street,North Usman Road, T Nagar,Chennai II Floor , Kences Towers No 1 Ramakrishna Street North Usman Road, T Nagar PIN: Tel No: 044-28140801 Fax No: 044-28142479 Email: [email protected] Internet: [email protected]
Management
C C Paarthipan, Chairman
Ashok Partheeban, Vice Chairman
Vivek Partheeban, Vice Chairman
Sridhar Ganesan, Managing Director
R Nagendran, Non Executive Independent Director
S Deenadhayalan, Non Executive Independent Director
R Vijayaraghavan, Non Executive Independent Director
KC John, Non Executive Independent Director
Susan Mathew, Non Executive Independent Director
G Venkatram, General Counsel, Company Secretary & Compliance Officer
Details
BSE 524742
NSE CAPLIPOINT
ISIN INE475E01026